Background: An invasive surgical operation, pelvic exenteration is only appropriate for a very restricted group of patients. Elderly patients who have surgery frequently have higher rates of morbidity and mortality. Examining the results of exenteration for advanced pelvic cancer in this patient subgroup was the goal of this investigation. Methods: The study included all patients who underwent pelvic exenteration between ‘January 2018 to January 2019’ and were at least 70 years old. This included all primary tumors of the bladder, gynaecological system, and rectal area. The 5-year overall survival was the main outcome measure. Post-operative morbidity and 30-day death were the secondary objectives. Results: There were 80 patients in all, ranging in age from 70 to 90 years old, with a median age of 75. Eight bladder tumors, 30 gynaecological, and 42 rectal tumors were found. The way that neoadjuvant therapy was administered varied significantly depending on the type of tumor. Within 30 days following surgery, five patients (5%) died and 30 patients (33%) experienced postoperative problems. Patients with rectal cancer had a median survival of 64 months, gynaecological tumor patients had a median survival of 30 months, and bladder cancer patients had a median survival of 15 months. The five-year survival rates for each of these groups were, respectively, 46, 30, and 21%.

Background: An invasive surgical operation, pelvic exenteration is only appropriate for a very restricted group of patients. Elderly patients who have surgery frequently have higher rates of morbidity and mortality. Examining the results of exenteration for advanced pelvic cancer in this patient subgroup was the goal of this investigation. Methods: The study included all patients who underwent pelvic exenteration between ‘January 2018 to January 2019’ and were at least 70 years old. This included all primary tumors of the bladder, gynaecological system, and rectal area. The 5-year overall survival was the main outcome measure. Post-operative morbidity and 30-day death were the secondary objectives. Results: There were 80 patients in all, ranging in age from 70 to 90 years old, with a median age of 75. Eight bladder tumors, 30 gynaecological, and 42 rectal tumors were found. The way that neoadjuvant therapy was administered varied significantly depending on the type of tumor. Within 30 days following surgery, five patients (5%) died and 30 patients (33%) experienced postoperative problems. Patients with rectal cancer had a median survival of 64 months, gynaecological tumor patients had a median survival of 30 months, and bladder cancer patients had a median survival of 15 months. The five-year survival rates for each of these groups were, respectively, 46, 30, and 21%.